Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection

John J. Engemann; Yehuda Carmeli; Sara E. Cosgrove; Vance G. Fowler; Melissa Z. Bronstein; Sharon L. Trivette; Jane P. Briggs; Daniel J. Sexton; Keith S. Kaye

doi:10.1086/367653

Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection

John J. Engemann, Yehuda Carmeli, Sara E. Cosgrove, Vance G. Fowler, Melissa Z. Bronstein, Sharon L. Trivette, Jane P. Briggs, Daniel J. Sexton, Keith S. Kaye

School of Medicine

Research output: Contribution to journal › Article › peer-review

735 Scopus citations

Abstract

Data for 479 patients were analyzed to assess the impact of methicillin resistance on the outcomes of patients with Staphylococcus aureus surgical site infections (SSIs). Patients infected with methicillin-resistant S. aureus (MRSA) had a greater 90-day mortality rate than did patients infected with methicillin-susceptible S. aureus (MSSA; adjusted odds ratio, 3.4; 95% confidence interval, 1.5-7.2). Patients infected with MRSA had a greater duration of hospitalization after infection (median additional days, 5; P<.001), although this was not significant on multivariate analysis (P = .11). Median hospital charges were $29,455 for control subjects, $52,791 for patients with MSSA SSI, and $92,363 for patients with MRSA SSI (P<.001 for all group comparisons). Patients with MRSA SSI had a 1.19-fold increase in hospital charges (P = .03) and had mean attributable excess charges of $13,901 per SSI compared with patients who had MSSA SSIs. Methicillin resistance is independently associated with increased mortality and hospital charges among patients with S. aureus SSI.

Original language	English (US)
Pages (from-to)	592-598
Number of pages	7
Journal	Clinical Infectious Diseases
Volume	36
Issue number	5
DOIs	https://doi.org/10.1086/367653
State	Published - Mar 1 2003

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1086/367653

Cite this

Engemann, J. J., Carmeli, Y., Cosgrove, S. E., Fowler, V. G., Bronstein, M. Z., Trivette, S. L., Briggs, J. P., Sexton, D. J., & Kaye, K. S. (2003). Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clinical Infectious Diseases, 36(5), 592-598. https://doi.org/10.1086/367653

@article{bd18d2f3d3c1463ca3ab31b50f2a7144,

title = "Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection",

abstract = "Data for 479 patients were analyzed to assess the impact of methicillin resistance on the outcomes of patients with Staphylococcus aureus surgical site infections (SSIs). Patients infected with methicillin-resistant S. aureus (MRSA) had a greater 90-day mortality rate than did patients infected with methicillin-susceptible S. aureus (MSSA; adjusted odds ratio, 3.4; 95% confidence interval, 1.5-7.2). Patients infected with MRSA had a greater duration of hospitalization after infection (median additional days, 5; P<.001), although this was not significant on multivariate analysis (P = .11). Median hospital charges were $29,455 for control subjects, $52,791 for patients with MSSA SSI, and $92,363 for patients with MRSA SSI (P<.001 for all group comparisons). Patients with MRSA SSI had a 1.19-fold increase in hospital charges (P = .03) and had mean attributable excess charges of $13,901 per SSI compared with patients who had MSSA SSIs. Methicillin resistance is independently associated with increased mortality and hospital charges among patients with S. aureus SSI.",

author = "Engemann, {John J.} and Yehuda Carmeli and Cosgrove, {Sara E.} and Fowler, {Vance G.} and Bronstein, {Melissa Z.} and Trivette, {Sharon L.} and Briggs, {Jane P.} and Sexton, {Daniel J.} and Kaye, {Keith S.}",

note = "Funding Information: Financial support: Unrestricted educational grant from Aventis Pharmaceuticals, fellowship from the Agency for Healthcare Research and Quality (to J.J.E.), and National Institutes of Health (grant AI-01647; to V.G.F.).",

year = "2003",

month = mar,

day = "1",

doi = "10.1086/367653",

language = "English (US)",

volume = "36",

pages = "592--598",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection

AU - Engemann, John J.

AU - Carmeli, Yehuda

AU - Cosgrove, Sara E.

AU - Fowler, Vance G.

AU - Bronstein, Melissa Z.

AU - Trivette, Sharon L.

AU - Briggs, Jane P.

AU - Sexton, Daniel J.

AU - Kaye, Keith S.

N1 - Funding Information: Financial support: Unrestricted educational grant from Aventis Pharmaceuticals, fellowship from the Agency for Healthcare Research and Quality (to J.J.E.), and National Institutes of Health (grant AI-01647; to V.G.F.).

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Data for 479 patients were analyzed to assess the impact of methicillin resistance on the outcomes of patients with Staphylococcus aureus surgical site infections (SSIs). Patients infected with methicillin-resistant S. aureus (MRSA) had a greater 90-day mortality rate than did patients infected with methicillin-susceptible S. aureus (MSSA; adjusted odds ratio, 3.4; 95% confidence interval, 1.5-7.2). Patients infected with MRSA had a greater duration of hospitalization after infection (median additional days, 5; P<.001), although this was not significant on multivariate analysis (P = .11). Median hospital charges were $29,455 for control subjects, $52,791 for patients with MSSA SSI, and $92,363 for patients with MRSA SSI (P<.001 for all group comparisons). Patients with MRSA SSI had a 1.19-fold increase in hospital charges (P = .03) and had mean attributable excess charges of $13,901 per SSI compared with patients who had MSSA SSIs. Methicillin resistance is independently associated with increased mortality and hospital charges among patients with S. aureus SSI.

AB - Data for 479 patients were analyzed to assess the impact of methicillin resistance on the outcomes of patients with Staphylococcus aureus surgical site infections (SSIs). Patients infected with methicillin-resistant S. aureus (MRSA) had a greater 90-day mortality rate than did patients infected with methicillin-susceptible S. aureus (MSSA; adjusted odds ratio, 3.4; 95% confidence interval, 1.5-7.2). Patients infected with MRSA had a greater duration of hospitalization after infection (median additional days, 5; P<.001), although this was not significant on multivariate analysis (P = .11). Median hospital charges were $29,455 for control subjects, $52,791 for patients with MSSA SSI, and $92,363 for patients with MRSA SSI (P<.001 for all group comparisons). Patients with MRSA SSI had a 1.19-fold increase in hospital charges (P = .03) and had mean attributable excess charges of $13,901 per SSI compared with patients who had MSSA SSIs. Methicillin resistance is independently associated with increased mortality and hospital charges among patients with S. aureus SSI.

UR - http://www.scopus.com/inward/record.url?scp=0037371388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037371388&partnerID=8YFLogxK

U2 - 10.1086/367653

DO - 10.1086/367653

M3 - Article

C2 - 12594640

AN - SCOPUS:0037371388

SN - 1058-4838

VL - 36

SP - 592

EP - 598

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 5

ER -

Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this